ask why
Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

The papers that matter: 10 November to 16 November 2025

The 10 most important of the 27 papers published that week and summarised on Y, ranked by what verified readers said would change practice, then by strength of design and size. Secondary analyses come last.
Women's health · Am J Obstet Gynecol MFM · 2025-11-14

Systematic review of 21 studies: slowing fetal growth velocity predicted small for gestational age poorly (AC sensitivity 0.22, specificity 0.92) but was moderately associated with adverse outcomes, eg perinatal death (pooled OR 3.92). No gain over biometry.

Meta-analysisn = 185,441 pregnancies
D'Alberti et al. Fetal growth velocity as a predictor of small for gestational age at birth and adverse perinatal outcomes: systematic review and meta-analysis
Oncology · Eur J Cancer · 2025-11-15

Meta-analysis of five RCTs (2380 women, FIGO stage III-IV ovarian cancer): neoadjuvant chemotherapy with interval surgery vs primary debulking showed no difference in OS (HR 1.00) or PFS (HR 1.03), with fewer grade ≥3 perioperative complications (RR 0.43).

Meta-analysisn = 2,380
Secchi et al. Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis
Transplantation · J Heart Lung Transplant · 2025-11-14

Long-term analysis of GRIPHON and its open-label extension in 953 selexipag-treated patients with pulmonary arterial hypertension: in 574 long-term patients (median follow-up 54 months), estimated 5-year survival was 74%; 39% stopped selexipag due to adverse events.

RCTn = 953
McLaughlin et al. Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extension
Addiction · Addict Behav · 2025-11-13

Pilot RCT of a smartphone alcohol approach bias modification app vs sham training in 188 adults ≥55 drinking at hazardous levels: no significant difference in past-week drinks at week 4 (β -1.90, p=.43); 56% retention. Feasibility and acceptability were good.

RCTn = 188
Bolt et al. AAT-App+: A double-blind, pilot randomised controlled trial of a novel personalised smartphone intervention to reduce hazardous and harmful alcohol consumption among middle-older adults

Previous weekNext weekAll weeks

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.